Jenscare Scientific Co. Ltd. Class H

Jenscare Scientific Co. Ltd. Class H

HHKEX:9877
5.64
HKD
-0.50
(-8.14%)
3.02BMarket Cap
Mar 31Next Earn
Jenscare Scientific Co. Ltd. Class H
HKEX:9877
(Hong Kong Exchange)

Recent

price

5.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
CNY
- -
- -
- -
- -
- -
0.21
- -
Revenue per Share
-0.72
-1.2
-1.2
-0.89
-0.43
-0.64
- -
Basic EPS, GAAP
-0.12
-0.38
-0.57
-0.72
-0.71
-0.19
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.85
3.09
3.29
2.96
2.23
1.89
1.8
Book Value per Share
0.84
3.09
3.28
2.95
2.22
1.88
1.78
Tangible Book Value per Share
417
417
365
417
409
425
405
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
91
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-253.26
- -
Operating Margin (%)
3
5
9
12
13
14
- -
Depreciation Expense
-299
-501
-439
-372
-178
-271
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-299.41
- -
Profit Margin (%)
337
779
799
1,096
622
515
471
Working Capital
2
1
2
42
46
17
29
LT Debt
353
1,291
1,373
1,226
917
773
734
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-60.91
-32.98
-28.53
-16.4
-31.52
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
41
30
11
LT Borrowings
16
16
28
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
417
417
417
Market Capitalization
3,209
3,336
2,617

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
648
621
550
Cash, Cash Equivalents & STI
531
527
415
Accounts Receivable, Net
6
7
28
Inventories
37
27
43
Total Current Liabilities
96
106
79
Payables & Accruals
- -
- -
- -
ST Debt
41
30
11
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
44.12%
-15.69%
Free Cash Flow
- -
43.79%
-72.32%
Net Income, GAAP
- -
8.02%
52.8%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
91
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.43
2025
- -
- -
-0.64
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Jenscare Scientific Co., Ltd. is a medical device company specializing in the research, development, manufacturing, and commercialization of innovative minimally invasive interventional therapies for structural heart diseases. Founded in November 2011 and headquartered in Ningbo, China, the company offers core products including the LuX-Valve series, a transcatheter tricuspid valve replacement system for severe tricuspid regurgitation; the Ken-Valve, designed for severe aortic regurgitation and combined aortic stenosis; the JensClip, a clip-based transcatheter mitral valve repair system for mitral regurgitation; the JensRelive transfemoral TMVR system; and the SimuLock left atrial appendage occluder for cardiogenic stroke prevention. Jenscare targets global markets and conducts clinical trials and commercialization preparations across regions including China, the U.S., and Europe. Major recent developments include advancing global commercialization of LuX-Valve Plus with significant clinical data release and ongoing registration trials internationally, the approval of Ken-Valve registration by China's National Medical Products Administration in early 2025, and the release of positive mid- and long-term clinical outcomes for their product portfolio. The company has demonstrated narrowing net losses and strong cash positions to support commercialization efforts and R&D activities. Jenscare continues expanding its product pipeline to address a broad spectrum of structural heart diseases and improve access to effective treatments globally.